When and how should potassium levels be monitored and managed in patients on MRAs?
Louise Moist, MD MSc CCPE FRCPC
When and why should patients with T2D have their UACR tested?
Navdeep Tangri, MD PhD, FRCPC
What data supports the use of novel nonsteroidal MRAs in patients already on an SGLT2 inhibitor?
Normand Proulx, MD, FRCP(C)
What are the key differences between steroidal MRAs and nonsteroidal MRAs?
Daniel Ngui, BScPT, PT, MD, CCFP, FCFP